Iron supplements inhibit zinc but not copper absorption in vivo in ileostomy subjects

Freddy J. Troost, Robert Jan M. Brummer, Jack R. Dainty, Jurian A. Hoogewerff, Vicky J. Bull, Wim H.M. Saris

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: Iron supplements may inhibit intestinal zinc and copper uptake because these elements may compete for binding to a transporter molecule (divalent metal transporter 1) that is located on the apical side of the small intestinal epithelium. Objective: We quantified the interaction between different amounts of administered iron and the absorption of zinc and copper in humans. Design: Eleven subjects with an ileostomy [mean (± SD) age: 55 ± 9 y] ingested a stable-isotope-labeled zinc and copper solution containing 12 mg Zn (66Zn and 67Zn) and 3 mg Cu ( 65Cu) in the presence of 0, 100, or 400 mg Fe as ferrous gluconate on 3 respective test days. Subsequently, 1 mg 70Zn was injected intravenously. Subjects collected ileostomy effluent and urine for 24 h and 7 d, respectively. Zinc status and true zinc absorption were calculated from the urinary excretion of the zinc isotopes. Apparent copper absorption was calculated from ileostomy effluent excretion of the orally administered copper isotopes. Results: Zinc status did not differ significantly between the 3 iron doses. Mean (± SEM) zinc absorption was significantly higher in the absence of iron than with the concomitant ingestion of 100 or 400 mg Fe (44 ± 22% compared with 26 ± 14% and 23 ± 6%, respectively; P < 0.05), whereas zinc absorption did not differ significantly between the 100- and 400-mg Fe doses. Apparent copper absorption was 48 ± 14%, 54 ± 26%, and 53 ± 7% in the presence of 0, 100, and 400 mg Fe, respectively, and did not differ significantly between the 3 iron doses. Conclusion: Oral iron therapy may impair zinc absorption and thus zinc status in a dose-independent fashion but does not affect copper absorption.

Original languageEnglish
Pages (from-to)1018-1023
Number of pages6
JournalAmerican Journal of Clinical Nutrition
Volume78
Issue number5
DOIs
Publication statusPublished - 2003
Externally publishedYes

Fingerprint

Ileostomy
Zinc
Copper
Iron
Zinc Isotopes
Intestinal Mucosa
Isotopes
Eating
Urine

Cite this

Troost, Freddy J. ; Brummer, Robert Jan M. ; Dainty, Jack R. ; Hoogewerff, Jurian A. ; Bull, Vicky J. ; Saris, Wim H.M. / Iron supplements inhibit zinc but not copper absorption in vivo in ileostomy subjects. In: American Journal of Clinical Nutrition. 2003 ; Vol. 78, No. 5. pp. 1018-1023.
@article{75558450e7a14572b408cf76b60fa1e2,
title = "Iron supplements inhibit zinc but not copper absorption in vivo in ileostomy subjects",
abstract = "Background: Iron supplements may inhibit intestinal zinc and copper uptake because these elements may compete for binding to a transporter molecule (divalent metal transporter 1) that is located on the apical side of the small intestinal epithelium. Objective: We quantified the interaction between different amounts of administered iron and the absorption of zinc and copper in humans. Design: Eleven subjects with an ileostomy [mean (± SD) age: 55 ± 9 y] ingested a stable-isotope-labeled zinc and copper solution containing 12 mg Zn (66Zn and 67Zn) and 3 mg Cu ( 65Cu) in the presence of 0, 100, or 400 mg Fe as ferrous gluconate on 3 respective test days. Subsequently, 1 mg 70Zn was injected intravenously. Subjects collected ileostomy effluent and urine for 24 h and 7 d, respectively. Zinc status and true zinc absorption were calculated from the urinary excretion of the zinc isotopes. Apparent copper absorption was calculated from ileostomy effluent excretion of the orally administered copper isotopes. Results: Zinc status did not differ significantly between the 3 iron doses. Mean (± SEM) zinc absorption was significantly higher in the absence of iron than with the concomitant ingestion of 100 or 400 mg Fe (44 ± 22{\%} compared with 26 ± 14{\%} and 23 ± 6{\%}, respectively; P < 0.05), whereas zinc absorption did not differ significantly between the 100- and 400-mg Fe doses. Apparent copper absorption was 48 ± 14{\%}, 54 ± 26{\%}, and 53 ± 7{\%} in the presence of 0, 100, and 400 mg Fe, respectively, and did not differ significantly between the 3 iron doses. Conclusion: Oral iron therapy may impair zinc absorption and thus zinc status in a dose-independent fashion but does not affect copper absorption.",
keywords = "Copper, Copper absorption, Ileostomy, Iron, Small intestine, Zinc, Zinc absorption",
author = "Troost, {Freddy J.} and Brummer, {Robert Jan M.} and Dainty, {Jack R.} and Hoogewerff, {Jurian A.} and Bull, {Vicky J.} and Saris, {Wim H.M.}",
year = "2003",
doi = "10.1093/ajcn/78.5.1018",
language = "English",
volume = "78",
pages = "1018--1023",
journal = "The Journal of clinical nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "5",

}

Iron supplements inhibit zinc but not copper absorption in vivo in ileostomy subjects. / Troost, Freddy J.; Brummer, Robert Jan M.; Dainty, Jack R.; Hoogewerff, Jurian A.; Bull, Vicky J.; Saris, Wim H.M.

In: American Journal of Clinical Nutrition, Vol. 78, No. 5, 2003, p. 1018-1023.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Iron supplements inhibit zinc but not copper absorption in vivo in ileostomy subjects

AU - Troost, Freddy J.

AU - Brummer, Robert Jan M.

AU - Dainty, Jack R.

AU - Hoogewerff, Jurian A.

AU - Bull, Vicky J.

AU - Saris, Wim H.M.

PY - 2003

Y1 - 2003

N2 - Background: Iron supplements may inhibit intestinal zinc and copper uptake because these elements may compete for binding to a transporter molecule (divalent metal transporter 1) that is located on the apical side of the small intestinal epithelium. Objective: We quantified the interaction between different amounts of administered iron and the absorption of zinc and copper in humans. Design: Eleven subjects with an ileostomy [mean (± SD) age: 55 ± 9 y] ingested a stable-isotope-labeled zinc and copper solution containing 12 mg Zn (66Zn and 67Zn) and 3 mg Cu ( 65Cu) in the presence of 0, 100, or 400 mg Fe as ferrous gluconate on 3 respective test days. Subsequently, 1 mg 70Zn was injected intravenously. Subjects collected ileostomy effluent and urine for 24 h and 7 d, respectively. Zinc status and true zinc absorption were calculated from the urinary excretion of the zinc isotopes. Apparent copper absorption was calculated from ileostomy effluent excretion of the orally administered copper isotopes. Results: Zinc status did not differ significantly between the 3 iron doses. Mean (± SEM) zinc absorption was significantly higher in the absence of iron than with the concomitant ingestion of 100 or 400 mg Fe (44 ± 22% compared with 26 ± 14% and 23 ± 6%, respectively; P < 0.05), whereas zinc absorption did not differ significantly between the 100- and 400-mg Fe doses. Apparent copper absorption was 48 ± 14%, 54 ± 26%, and 53 ± 7% in the presence of 0, 100, and 400 mg Fe, respectively, and did not differ significantly between the 3 iron doses. Conclusion: Oral iron therapy may impair zinc absorption and thus zinc status in a dose-independent fashion but does not affect copper absorption.

AB - Background: Iron supplements may inhibit intestinal zinc and copper uptake because these elements may compete for binding to a transporter molecule (divalent metal transporter 1) that is located on the apical side of the small intestinal epithelium. Objective: We quantified the interaction between different amounts of administered iron and the absorption of zinc and copper in humans. Design: Eleven subjects with an ileostomy [mean (± SD) age: 55 ± 9 y] ingested a stable-isotope-labeled zinc and copper solution containing 12 mg Zn (66Zn and 67Zn) and 3 mg Cu ( 65Cu) in the presence of 0, 100, or 400 mg Fe as ferrous gluconate on 3 respective test days. Subsequently, 1 mg 70Zn was injected intravenously. Subjects collected ileostomy effluent and urine for 24 h and 7 d, respectively. Zinc status and true zinc absorption were calculated from the urinary excretion of the zinc isotopes. Apparent copper absorption was calculated from ileostomy effluent excretion of the orally administered copper isotopes. Results: Zinc status did not differ significantly between the 3 iron doses. Mean (± SEM) zinc absorption was significantly higher in the absence of iron than with the concomitant ingestion of 100 or 400 mg Fe (44 ± 22% compared with 26 ± 14% and 23 ± 6%, respectively; P < 0.05), whereas zinc absorption did not differ significantly between the 100- and 400-mg Fe doses. Apparent copper absorption was 48 ± 14%, 54 ± 26%, and 53 ± 7% in the presence of 0, 100, and 400 mg Fe, respectively, and did not differ significantly between the 3 iron doses. Conclusion: Oral iron therapy may impair zinc absorption and thus zinc status in a dose-independent fashion but does not affect copper absorption.

KW - Copper

KW - Copper absorption

KW - Ileostomy

KW - Iron

KW - Small intestine

KW - Zinc

KW - Zinc absorption

UR - http://www.scopus.com/inward/record.url?scp=0642341489&partnerID=8YFLogxK

U2 - 10.1093/ajcn/78.5.1018

DO - 10.1093/ajcn/78.5.1018

M3 - Article

VL - 78

SP - 1018

EP - 1023

JO - The Journal of clinical nutrition

JF - The Journal of clinical nutrition

SN - 0002-9165

IS - 5

ER -